JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer

  • 0Department of Medical Oncology, Wuxi Huishan District People' s Hospital, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi, China.
Cancer Control : Journal of the Moffitt Cancer Center +

|

February 12, 2025

|

February 12, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Tumor burden (TB) significantly impacts immunotherapy efficacy in advanced non-small cell lung cancer (NSCLC). Higher TB correlates with poorer survival, suggesting TB is a key prognostic biomarker for treatment response.

Area Of Science

  • Oncology
  • Immunotherapy
  • Biomarker Discovery

Background

  • Advanced non-small cell lung cancer (NSCLC) poses significant treatment challenges.
  • Immunotherapy has emerged as a crucial treatment modality for NSCLC.
  • Predictive biomarkers are essential for optimizing immunotherapy efficacy.

Purpose Of The Study

  • To evaluate the impact of tumor burden (TB) on immunotherapy efficacy in advanced NSCLC.
  • To determine if TB can serve as a prognostic biomarker for clinical benefit.
  • To assess TB's accuracy in predicting mortality in NSCLC patients receiving atezolizumab.

Main Methods

  • Cohort study utilizing data from POPLAR and OAK trials (N=427).
  • Tumor burden (TB) defined by RECIST v1.1 sum of longest dimensions (blSLD).
  • Kaplan-Meier curves, Cox regression, and random forest algorithms used for analysis.

Main Results

  • Patients with lower tumor burden (TB-L) showed significantly better overall survival (OS) than those with higher tumor burden (TB-H) in both training and validation cohorts.
  • TB independently predicted OS, irrespective of blood-tested tumor mutation burden (bTMB) or PD-L1 expression.
  • Increased TB was associated with a stronger detrimental effect on 12-month mortality.

Conclusions

  • Tumor burden (TB) is a potential prognostic biomarker for immunotherapy efficacy in NSCLC.
  • TB may help predict clinical benefit from immunotherapy regimens in NSCLC patients.
  • Further validation of TB as a predictive biomarker is warranted.

Keywords: